论文部分内容阅读
目的:探讨HER-2基因在乳腺癌中的表达及其与雌激素受体亚型(ERα、ERβ)之间的关系。方法:应用免疫组化EnVision二步法检测155例手术切除的乳腺癌标本中的HER-2、ERα、ERβ的表达。比较在不同临床参数下(绝经、肿块直径、淋巴结转移、远处转移及TNM分期)HER-2的表达差异,并对HER-2、ERα、ERβ三者之间的相关性进行分析。结果:155例标本中HER-2、ERα、ERβ的阳性表达率分别为57.4%(89/155)、68.4%(106/155)、42.6%(66/155)。HER-2在肿块≤2 cm、TNM分期Ⅰ期乳腺癌、无淋巴结转移患者中的表达明显低于在肿块>2 cm、Ⅱ+Ⅲ+Ⅳ期乳腺癌、有淋巴结转移患者中的表达(P<0.001、P<0.05、P<0.01)。相关性分析显示,HER-2与ERα的表达呈负相关(r=-0.47,P<0.001),而HER-2与ERβ以及ERα与ERβ的表达之间无显著相关性。结论:HER-2可作为判断乳腺癌预后的重要指标,且同ERα的表达呈负相关。
Objective: To investigate the expression of HER-2 in breast cancer and its relationship with estrogen receptor subtypes (ERα, ERβ). Methods: The expression of HER-2, ERα, ERβ in 155 surgically resected breast cancer specimens was detected by immunohistochemistry EnVision two-step method. The differences of HER-2 expression between different clinical parameters (menopause, tumor diameter, lymph node metastasis, distant metastasis and TNM stage) were compared. The correlation between HER-2, ERα and ERβ was analyzed. Results: The positive rates of HER-2, ERα and ERβ in 155 specimens were 57.4% (89/155), 68.4% (106/155) and 42.6% (66/155), respectively. The expression of HER-2 in patients with TNM stage Ⅰ breast cancer and without lymph node metastasis was significantly lower than that in patients with lymph node metastasis (P> <0.001, P <0.05, P <0.01). Correlation analysis showed that there was a negative correlation between the expression of HER-2 and ERα (r = -0.47, P <0.001), but there was no significant correlation between HER-2 and ERβ and the expression of ERα and ERβ. Conclusion: HER-2 can be used as an important index to judge the prognosis of breast cancer, and negatively correlated with the expression of ERα.